We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.24%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$384M
AUM Growth
-$13.9M
Cap. Flow
+$77.9M
Cap. Flow %
20.3%
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24.9M
2
IBB icon
iShares Biotechnology ETF
IBB
+$8.02M
3
FATE icon
Fate Therapeutics
FATE
+$4.99M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$4.59M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.37M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.1M
2
OTIC
Otonomy, Inc.
OTIC
+$1.49M
3
HOOK
HOOKIPA Pharma
HOOK
+$747K
4
PRQR icon
ProQR Therapeutics
PRQR
+$685K
5
XENE icon
Xenon Pharmaceuticals
XENE
+$674K

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
26
Arcus Biosciences
RCUS
$3.61B
$4.58M 1.19%
145,217
+28,017
+24% +$939K
ALEC icon
27
Alector
ALEC
$203M
$4.17M 1.09%
292,747
+137,500
+89% +$2.17M
OTIC
28
DELISTED
Otonomy, Inc.
OTIC
$3.59M 0.94%
1,497,514
-702,783
-32% -$1.49M
ASND icon
29
Ascendis Pharma A/S
ASND
$16.4B
$3.59M 0.94%
30,612
+19,612
+178% +$2.27M
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.51M 0.91%
+42,700
New +$4.37M
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.78B
$3.46M 0.9%
+356,750
New +$4.59M
IPSC icon
32
Century Therapeutics
IPSC
$343M
$3.23M 0.84%
256,892
+156,757
+157% +$2.08M
ARAY icon
33
Accuray
ARAY
$33.8M
$3.12M 0.81%
941,800
– –
PRDS
34
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$3.04M 0.79%
421,157
+187,657
+80% +$1.85M
REUN
35
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$2.94M 0.77%
438,262
+370,082
+543% +$3.08M
ITOS
36
DELISTED
iTeos Therapeutics
ITOS
$2.87M 0.75%
89,298
+35,208
+65% +$1.28M
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
$2.81M 0.73%
190,663
– –
RIGL icon
38
Rigel Pharmaceuticals
RIGL
$733M
$2.68M 0.7%
89,610
+1,710
+2% +$46.3K
LKFT
39
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$2.65M 0.69%
42,675
– –
AXGN icon
40
Axogen
AXGN
$2.38B
$2.64M 0.69%
332,103
– –
AERI
41
DELISTED
Aerie Pharmaceuticals
AERI
$2.63M 0.69%
289,040
– –
AFMD
42
DELISTED
Affimed
AFMD
$2.5M 0.65%
57,128
– –
FSTX
43
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.46M 0.64%
693,785
– –
BCYC
44
Bicycle Therapeutics
BCYC
$278M
$2.33M 0.61%
+53,200
New +$2.48M
LONA
45
LeonaBio Inc
LONA
$73.4M
$2.17M 0.57%
16,098
– –
AUTL
46
Autolus Therapeutics
AUTL
$532M
$2.07M 0.54%
+496,150
New +$2.09M
SURF
47
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2M 0.52%
680,000
+365,000
+116% +$1.28M
KURA icon
48
Kura Oncology
KURA
$824M
$1.82M 0.47%
113,329
+2,500
+2% +$36.1K
DICE
49
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$1.8M 0.47%
+94,000
New +$1.68M
BWAY
50
Brainsway
BWAY
$628M
$1.75M 0.46%
400,000
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, DAFNA Capital Management held 98 positions worth $384M, down 3.5% from $398M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $77.9M of net new capital in Q1 2022, opening 11 new positions and adding to 36 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Otonomy, Inc., an estimated $1.49M trimmed.

  • DAFNA Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q1 2022, an estimated $8.02M increase.
  • DAFNA Capital Management's biggest Q1 2022 reduction was Otonomy, Inc., cutting an estimated $1.49M.
  • DAFNA Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $11.1M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $384M portfolio in Q1 2022.
  • DAFNA Capital Management opened 11 new positions and closed 4 in Q1 2022.
  • DAFNA Capital Management's portfolio value fell 3.5% quarter-over-quarter to $384M.

Based on DAFNA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.